Is Novo Nordisk (NYSE:NVO) a full-fledged pharmaceutical company, or does it fall into that "specialty pharmaceutical" niche? Will the company succeed in expanding beyond diabetes and very specialized hormone/protein therapies? Does anybody care so long as the company delivers double-digit revenue growth and returns on capital that approach 40%?

TUTORIAL: Stock Basics

The Strong Get Stronger in Q1
While some analysts seem to be fretting a bit about a "slowdown" in the insulin business for Novo Nordisk, the fact remains that this is one of the fastest-growing major pharmaceutical companies on the planet. Total revenue rose 15% this quarter, with the diabetes franchise growing 16% and the biopharmaceuticals business up 10%. Within diabetes, insulins grew 8% due to continued growth of the analog platform, while Victoza showed nearly 200% growth and delivered over $200 million in revenue on its way to blockbuster status.

Profitability also improved this quarter. Gross margin slid a bit as the company could not completely offset a drag from foreign currency, but the loss was limited to 20 basis points. Operating income grew 24%, though, as sales, administrative and R&D expenses all grew by mid-single-digit amounts. Although the R&D spend looked a bit light this quarter, it looks like more of a timing issue than any sort of philosophical change.

The Diabetes Fortress Still Strong
Novo Nordisk is demonstrating why diabetes is a great franchise for drug companies; the products have to be used over and over again and the reimbursement is strong. Although the company lost some insulin analog share in the United States because of a few managed care contracts that went to Lilly (NYSE:LLY), there is nothing going on in the market that suggests the company is really losing any meaningful ground to Lilly or Sanofi-Aventis (NYSE:SNY) in this market. Likewise, the company is clearly having no problems competing with Merck's (NYSE:MRK) Januvia or Bristol-Myers' (NYSE:BMY) Onglyza.

At the same time, the FDA and would-be competitor missteps are limiting competition. The FDA rejected new insulin formulations from Biodel (Nasdaq:BIOD) and MannKind (Nasdaq:MNKD), and it is unclear if either of these companies will succeed in securing approvals for their oral and inhaled insulin products. Elsewhere, the prospects for Victoza got a big boost from the FDA setback with Bydureon, an anti-diabetes medication that Lilly hopes to co-market as a follow-up to the successful GLP-1 drug Byetta.

An Interesting, but Mixed, Pipeline
As is often the case, Novo had a mix of good and disappointing news on its pipeline. The company is abandoning an oral rapid-acting insulin, while still working on a longer-acting formulation. Data on a would-be rival to Sanofi's Lantus appears to be viable for approval and competitive launch. The company advanced two compounds into Phase 2 studies for rheumatoid arthritis and Crohn's disease (and these are potentially valuable expansions into antibody therapy), but also reported that trials for new applications for Factor 7a and 13 failed.

The Bottom Line
Novo Nordisk clearly stands out from Astra Zeneca (NYSE:AZN), Novartis (NYSE:NVS) and Sanofi-Aventis as a great growth-oriented European pharmaceutical company. It also stands out in terms of its valuation. For investors who doubt just how much investors hate uncertainty and will reward reliable growth (with moderate competitive threats), Novo Nordisk is a great example.

Even allowing for strong ongoing growth in free cash flow and a generous discount rate, Novo Nordisk shares do not look cheap enough today. Though this would be a fantastic stock to buy on a pullback or market correction, it just seems too expensive today. (For related reading, also take a look at Pharmaceutical Sector: Does The FDA Help Or Harm?)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  7. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  8. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  9. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  10. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center